CGAS and cancer: In addition to the more traditional anti-cancer therapies, more recently-developed targeted therapies, such as DNA damage response (DDR) inhibitors (e.g., PARP inhibitors, Chk inhibitors, DNA-PK inhibitors, ATR inhibitors), also activate cGAS-STING signaling and prompt the downstream immune components entailed [74] (Figure 4A).